A Study to Evaluate the Efficacy and Safety of AD-209

Phase 2CompletedNCT05631990

Addpharma Inc.221 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of AD-209

Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

221

Conditions

Hypertension, Essential

Interventions

AD-209DRUG

PO, Once daily(QD), 8weeks

AD-209-1ADRUG

PO, Once daily(QD), 8weeks

AD-209-1BDRUG

PO, Once daily(QD), 8weeks

AD-209-1C

Eligibility

Sex: ALLMin age: 19 YearsMax age: 74 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * orthostatic hypotension with symptom * Other exclusions applied

Locations (1)

Korea University Guro Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Change rate of MSSBP

Change from baseline in mean sitting systolic blood pressure

Time frame: Baseline, Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.